Mangalam Drugs & Organics Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Mangalam Drugs & Organics.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.6%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors

Aug 13

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

May 23

Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Mar 28

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Feb 07

Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Oct 20

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Mar 29

These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

May 31

A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Apr 06

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Jan 03

Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

May 23

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Jan 04

Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

Nov 12

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Sep 20

Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

Aug 05

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

Jul 01

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Mangalam Drugs & Organics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:MANGALAM - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	3,674	-91	N/A	N/A	N/A
12/31/2023	3,595	-170	N/A	N/A	N/A
9/30/2023	3,245	-171	N/A	N/A	N/A
6/30/2023	3,477	-113	N/A	N/A	N/A
3/31/2023	3,702	13	116	395	N/A
12/31/2022	4,109	123	N/A	N/A	N/A
9/30/2022	4,426	159	44	279	N/A
6/30/2022	4,505	182	N/A	N/A	N/A
3/31/2022	4,509	197	-20	257	N/A
12/31/2021	4,185	151	N/A	N/A	N/A
9/30/2021	4,058	175	-73	315	N/A
6/30/2021	3,813	241	N/A	N/A	N/A
3/31/2021	3,800	280	-39	275	N/A
12/31/2020	3,774	309	N/A	N/A	N/A
9/30/2020	3,507	261	221	361	N/A
6/30/2020	3,210	158	N/A	N/A	N/A
3/31/2020	2,824	83	236	305	N/A
12/31/2019	2,423	-28	N/A	N/A	N/A
9/30/2019	2,290	-89	N/A	N/A	N/A
6/30/2019	2,336	-80	N/A	N/A	N/A
3/31/2019	2,276	-80	124	217	N/A
12/31/2018	2,467	10	N/A	N/A	N/A
9/30/2018	2,720	114	N/A	N/A	N/A
6/30/2018	2,833	164	N/A	N/A	N/A
3/31/2018	2,794	199	86	246	N/A
12/31/2017	2,904	247	N/A	N/A	N/A
9/30/2017	2,983	248	N/A	N/A	N/A
6/30/2017	3,044	233	N/A	N/A	N/A
3/31/2017	3,029	223	N/A	428	N/A
12/31/2016	2,906	227	N/A	N/A	N/A
9/30/2016	2,943	203	N/A	N/A	N/A
6/30/2016	2,919	181	N/A	N/A	N/A
3/31/2016	2,952	160	N/A	218	N/A
12/31/2015	3,001	140	N/A	N/A	N/A
9/30/2015	2,807	110	N/A	N/A	N/A
6/30/2015	2,516	101	N/A	N/A	N/A
3/31/2015	2,207	61	N/A	140	N/A
12/31/2014	1,783	65	N/A	N/A	N/A
9/30/2014	1,556	56	N/A	N/A	N/A
6/30/2014	1,425	26	N/A	N/A	N/A
3/31/2014	1,227	-30	N/A	75	N/A
12/31/2013	1,320	-60	N/A	N/A	N/A
9/30/2013	1,293	-84	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de MANGALAM es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de MANGALAM crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de MANGALAM crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de MANGALAM crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de MANGALAM crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MANGALAM se prevé que sea elevada dentro de 3 años.

Mangalam Drugs & Organics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors

Mangalam Drugs & Organics Limited to Report Q1, 2025 Results on Aug 13, 2024

Mangalam Drugs & Organics Limited to Report Q1, 2025 Results on Aug 13, 2024

Mangalam Drugs & Organics Limited Appoints Ms. Anuradha Pandey as Company Secretary, Compliance Officer and Key Managerial Personnel

New major risk - Financial position

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited, Annual General Meeting, May 21, 2024

Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding

Now 22% undervalued

Third quarter 2024 earnings released: EPS: ₹0.31 (vs ₹0.27 in 3Q 2023)

Now 24% undervalued

Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business

Second quarter 2024 earnings released: ₹2.26 loss per share (vs ₹1.41 profit in 2Q 2023)

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

First quarter 2024 earnings released: ₹6.02 loss per share (vs ₹1.92 profit in 1Q 2023)

Mangalam Drugs & Organics Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: EPS: ₹0.80 (vs ₹12.42 in FY 2022)

Mangalam Drugs & Organics Limited to Report Q4, 2023 Results on May 30, 2023

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Third quarter 2023 earnings released: EPS: ₹0.27 (vs ₹2.54 in 3Q 2022)

Mangalam Drugs & Organics Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: EPS: ₹1.41 (vs ₹2.86 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹1.41 (vs ₹2.86 in 2Q 2022)

Mangalam Drugs & Organics Limited to Report Q2, 2023 Results on Nov 11, 2022

Mangalam Drugs & Organics Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: EPS: ₹1.92 (vs ₹2.79 in 1Q 2022)

Mangalam Drugs & Organics Limited to Report Q1, 2023 Results on Aug 05, 2022

Chairman & MD recently sold ₹1.3m worth of stock

Investor sentiment improved over the past week

These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively

Full year 2022 earnings released: EPS: ₹12.42 (vs ₹17.67 in FY 2021)

Mangalam Drugs & Organics Limited to Report Q4, 2022 Final Results on May 26, 2022

Investor sentiment improved over the past week

A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

Mangalam Drugs & Organics Limited Announces Executive Changes

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt

Investor sentiment improved over the past week

Insufficient new directors

Insufficient new directors

First quarter 2022 earnings released: EPS ₹2.79 (vs ₹6.13 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly

Full year 2021 earnings released: EPS ₹17.67 (vs ₹5.21 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹112

Third quarter 2021 earnings released: EPS ₹4.07 (vs ₹1.04 in 3Q 2020)

Mangalam Drugs & Organics Limited to Report Q3, 2021 Results on Feb 11, 2021

New 90-day low: ₹127

Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?

Mangalam Drugs & Organics Limited Announces Resignation of Prashant J. Pandit as Independent Director

New 90-day low: ₹129

Mangalam Drugs & Organics Limited Announces Change in Directorate

New 90-day high: ₹169

Second quarter 2021 earnings released: EPS ₹7.00

Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?

A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)

New 90-day high - ₹90.80

Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?

Mangalam Drugs & Organics Limited to Report Q1, 2021 Results on Aug 10, 2020

We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt

Mangalam Drugs & Organics Limited to Report Q4, 2020 Results on Jun 29, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento